Dr Paula Wells

Dr Paula Wells

Clinical oncology 03120550


  • Bupa Platinum consultant
  • Fee assured
  • Open Referral network
Bupa Platinum consultant
Fee assured
Open Referral network

Specialises in

  • Lung
  • Urology


  • Face-to-face consultations
  • Video and telephone consultations
  • Home chemotherapy

About me

My oncology training was undertaken at St. Bartholomew’s, UCLH and Mount Vernon Hospitals. Following my Fellowship, I undertook a postgraduate research degree at Imperial College School of Medicine, Hammersmith Hospital. There I investigated the potential for Positron Emission Tomography (PET) to demonstrate the biological effects of chemotherapy in tissue.
I have published a number of papers in this area and was awarded a PhD for my work. Subsequently I completed my post doctoral training at the Royal Marsden Hospital, principally with the Academic Urology Unit.
I specialise in the management of patients with genitourinary (bladder and prostate) and thoracic (lung and mesothelioma) malignancies. Furthermore I have significant expertise in the delivery of real time dynamic prostate low dose rate (LDR) brachytherapy for patients with early stage, localised prostate cancer. I am also a registered Cyberknife practitioner with a National referral practice and deliver stereotactic radiotherapy (SABR) in both the radical and palliative (for metastatic disease) setting.

Since taking up my present post I have been extensively involved with the development of the genitourinary and thoracic cancer services for the North East London Cancer Network and London Cancer.

I am an active participant in UK clinical trials and am principal investigator for the North East London Cancer Network for a number of studies. I introduced Intensity Modulated (IMRT) and image guided (IGRT) radiotherapy to my NHS practice in 2010, which was mirrored in my private work. I have significant experience in chemo-radiation in bladder and lung cancer and stereotactic radiotherapy for lung and prostate cancer in the radical setting and the treatment of oligometastatic disease for all tumour sites including brain. My research interest in PET continues to develop with an emphasis on investigating the direct effects of radiotherapy on tissue and the effect of integration of novel therapies with radiation.

Areas of interest

• Bladder Cancer • Prostate Cancer • Mesothelioma • Lung cancer • Cyberknife • Prostate brachytherapy; chemotherapy; targeted therapy; immunotherapy

Medical secretaries

About me
My qualifications & training
My private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • X0004

    Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (>50)

    HCA - Leaders in Oncology Care (5-50)

  • X0007

    Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (1-5)

  • X6950

    Clinical supervision of the planning of stereotactic radiosurgery e.g. SRT/SBRT and Gamma Knife - (1-5)

    HCA - Leaders in Oncology Care (1-5)

  • X0008

    Clinical supervision of external beam radiotherapy, for 16 or up to and including 30 fractions - (1-5)

  • A1070

    Stereotactic radiotherapy (SRT), first/sole session using Cyberknife or similar SRT technology - (1-5)

  • X6772

    Preparation for complex radiotherapy with Intensity Modulated Radiotherapy (IMRT) - (1-5)

  • Show All (7 )...
Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.